Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...
WASHINGTON–A new initiative by The Society for Cardiovascular Angiography & Interventions (SCAI) proposes a new framework and call to action for managing cardiogenic shock (CS), establishing lactate ...
The Society for Cardiovascular Angiography and Interventions (SCAI) has refined its cardiogenic shock (CS) classification system based on the literature and clinician feedback from real-world ...
Please provide your email address to receive an email when new articles are posted on . The SCAI shock classification system may provide mortality risk stratification of patients at risk for or who ...
WASHINGTON, DC—Early-stage cardiogenic shock leads to poor outcomes but is underrecognized, with only one in four affected patients having any indication in their electronic medical record (EMR) that ...
WARRINGTON, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for ...
CHICAGO -- Unexpectedly, early extracorporeal membrane oxygenation (ECMO) did not help outcomes in severe or rapidly progressing cardiogenic shock, the ECMO-CS randomized trial found. What appeared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results